solid tumor

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win

The phase 3 trial hit at least one primary endpoint, boosting the prospects of a candidate that BMS licensed outside China for $800 million upfront.
Nick Paul Taylor Jul 2, 2025 9:53am
End of road sign on street

Oncternal sells cancer assets to mystery biotech, winds down ops

Jul 1, 2025 9:38am
An arrow incrementally going up stairs before pointing straight up Blue background

Merck KGaA posts tumor data ahead of showdown with Daiichi, Ono

May 28, 2025 8:45am
Large layoffs of employees Wooden figures of people going to the exit

Boundless Bio lays off 33% of staff as lead program stumbles

May 27, 2025 8:40am
pile of cash piggy bank money cash dollars bills spend

Pathos AI's $365M series D to fund trial of Novo tumor drug

May 15, 2025 10:20am
time minute

Enliven calls time on phase 1 HER2 solid tumor program

May 15, 2025 7:50am